Working from home can seem like the perfect solution for a migraineur. When a migraine strikes, you are already in an environment where you have ready access to dark rooms and medication. However, if working from home is not a normal part of your routine, you may feel more stressed than usual.
The misdiagnosis of migraine is common. Around half of people presenting with headache pain are not diagnosed correctly as to its cause. So, there is already an issue present that can become more challenging for women.
While the popularity of cannabidiol (CBD) continues to soar, there are still few studies available with data to support its use. Now that industrial hemp farming is legal, studies of hemp oil and CBD on migraines may become more available. Confounding some of the efforts is the fact that, while CBD is legal at the federal level, it is still illegal in some states. However, the trend appears to be toward the legalization of CBD in certain forms.
People suffering from acute migraines will soon have another rescue medication at their disposal - The FDA approved Reyvow (lasmiditan hemisuccinate). The US Drug Enforcement Administration (DEA) has 90 days to review the drug to determine if it will be classified as a controlled substance. Once that three-month period is complete, the maker, Eli Lilly, and Company expect it to be available at retail pharmacies.
When a migraine doesn't respond to any other treatment, ketamine may offer relief. Operating differently than opioids, non-steroidal anti-inflammatories, and triptans, ketamine is increasingly available to treat chronic pain, migraine, and other health issues.
Within the past decade, electrical nerve stimulation has been introduced as a potential non-drug treatment for individuals suffering migraines or cluster headaches. The approach varies slightly between techniques, and depending on the method, can be invasive or non-invasive.
Migraines come in several flavors, but one of the primary classifications is that of episodic migraine. Episodic migraines differ from chronic migraine disorder and may respond better to some treatments than chronic migraines.
“Given the opioid epidemic in the U.S. and the high prevalence of opioid use in migraine patients shown in our study, especially those with chronic migraine, our results suggest that improved management of treatment is needed to optimize care.” - Justin S. Yu, PharmS, Allergan
Good news for those of you who suffer from cluster headaches. On June 4, the FDA announced it has approved Galcanezumab, sold as Emgality by Eli Lilly and Co., for the treatment of episodic cluster headaches.
Among the many physiological and environmental conditions believed to cause migraines, decreased oxygen levels and vasoconstriction of the blood flow in the brain are two of the most often cited by medical researchers.
